A groundbreaking study by the University of Oxford has revealed a crucial benefit of COVID-19 vaccines: their effectiveness in reducing the risk of long COVID.
This study, led by Dani Prieto-Alhambra, Professor of Pharmaco- and Device Epidemiology, fills a significant gap in our understanding of the long-term impact of these vaccines.
Despite the rapid development and widespread distribution of various COVID-19 vaccines, questions remained about their ability to prevent long COVID—a condition where symptoms persist well beyond the initial infection.
To explore this, the team secured funding from the National Institute for Health and Care Research (NIHR) and embarked on an extensive research project.
The study, published in The Lancet Respiratory Medicine, utilized primary care electronic health records from the UK, Spain, and Estonia.
Involving over 20 million vaccinated and unvaccinated individuals, the research was meticulous in its approach, identifying cases of long COVID based on specific criteria set by the World Health Organization (WHO).
One of the study’s key findings is a marked decrease in the occurrence of long COVID among vaccinated individuals.
Dr. Annika Jodicke, senior pharmacoepidemiologist and co-lead of the study, noted that both vaccines were effective in preventing persistent COVID symptoms.
Particularly notable was the comparison between different vaccines: the BNT162b2 vaccine (BioNTech/Pfizer) demonstrated superior protection against long COVID compared to the ChAdOx1 vaccine (Oxford/AstraZeneca).
Dr. Marti Catala, Senior Data Scientist and lead author of the manuscript, emphasized the consistency of these findings across different countries and populations.
The study’s replication of analyses using data from Spain and Estonia further underscored the vital role vaccinations play in protecting individuals from long-term effects of COVID-19.
This research not only underscores the importance of vaccination in combating the acute phases of COVID-19 but also highlights its crucial role in preventing the prolonged, debilitating effects of long COVID.
By providing robust evidence of the vaccines’ protective effect against long-term symptoms, the study offers valuable insights for public health strategies and individual decisions regarding COVID-19 vaccination.
If you care about COVID, please read studies about new evidence on rare blood clots after COVID-19 vaccination, and how diets could help manage post-COVID syndrome.
For more information about health, please see recent studies about COVID infection and vaccination linked to heart disease, and results showing extracts from two wild plants can inhibit COVID-19 virus.
The research findings can be found in The Lancet Respiratory Medicine.
Copyright © 2024 Knowridge Science Report. All rights reserved.
